David Paulson, MD
Psychiatry · Orem, UTNPI 1740252196
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 25.4% of the total. Among psychiatry clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$423
- Otsuka America Pharmaceutical, Inc.$195
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$183
- Lundbeck LLC$169
- Takeda Pharmaceuticals U.S.A., Inc.$97
- Johnson & Johnson$87
- plus $509 from 15 others
What the payments were for
- Food & beverage$1,57094%
- Education$946%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $423 |
| Otsuka America Pharmaceutical, Inc. | 12 | $195 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $183 |
| Lundbeck LLC | 9 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $97 |
| Johnson & Johnson | 5 | $87 |
| Sunovion Pharmaceuticals Inc. | 9 | $66 |
| Axsome Therapeutics, Inc. | 3 | $62 |
| Supernus Pharmaceuticals, Inc. | 3 | $53 |
| Vanda Pharmaceuticals Inc. | 3 | $50 |
| Tris Pharma Inc | 3 | $48 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Harmony Biosciences LLC | 2 | $35 |
| Ironshore Pharmaceuticals Inc. | 1 | $30 |
| Alkermes, Inc. | 1 | $26 |
| Corium, LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Neuronetics, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $14 |
How this compares
$1,664 in reported general payments places this provider in the 90th percentile of 231 psychiatry providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LatudaLurasidone Hcl | 15 | $40,866 |
| CaplytaLumateperone Tosylate | 15 | $23,832 |
| Lurasidone Hcl | 33 | $16,763 |
| VraylarCariprazine Hcl | 11 | $16,169 |
| TrintellixVortioxetine Hydrobromide | 24 | $16,042 |
| ZoloftSertraline Hcl | 15 | $14,090 |
| BelsomraSuvorexant | 14 | $9,718 |
| Quetiapine Fumarate | 68 | $2,433 |
| Lamotrigine | 111 | $2,083 |
| Armodafinil | 22 | $2,041 |
| Duloxetine Hcl | 55 | $1,480 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $1,338 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 55 | $1,313 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 15 | $1,306 |
| Dextroamphetamine Sulfate | 15 | $1,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sunovion Pharmaceuticals Inc.Latuda | $66 | $40,86615 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $183 | $23,83215 claims |
| AbbVieVraylar | $423 | $16,16911 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $97 | $16,04224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 231 psychiatry providers in Utah.
Other psychiatry in Orem
- Reid RobisonOrem$133K
- Michael MeasomSlc$2.2M
- Noel GardnerSalt Lake City$512K
- Thomas RaynerProvo$60K
- Trent HolmbergDraper$32K
- Nathan CurrierRiverton$21K
- Oliver McPhersonBountiful$20K
- Frederick ReimherrSalt Lake City$18K
- Lisa FraleighLogan$8K
- Clark JohnsonSalt Lake City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.